Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging

Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia

(2018) Lorenzo Guglielmetti et al.   EUROPEAN RESPIRATORY JOURNAL

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa

(2018) Erika Mohr et al.   EUROPEAN RESPIRATORY JOURNAL

Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa

(2018) Olatunde Olayanju et al.   EUROPEAN RESPIRATORY JOURNAL

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

(2018) Gabriella Ferlazzo et al.   LANCET INFECTIOUS DISEASES

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

(2018) Simon Tiberi et al.   LANCET INFECTIOUS DISEASES

Bedaquiline: how better to use it

(2017) Jose A. Caminero et al.   EUROPEAN RESPIRATORY JOURNAL

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence

(2017) Emanuele Pontali et al.   EUROPEAN RESPIRATORY JOURNAL

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study

(2017) Sergey E. Borisov et al.   EUROPEAN RESPIRATORY JOURNAL

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India

(2017) Zarir F. Udwadia et al.   EUROPEAN RESPIRATORY JOURNAL

Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis

(2017) Ioana D. Olaru et al.   EUROPEAN RESPIRATORY JOURNAL

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens

(2017) Liga Kuksa et al.   EUROPEAN RESPIRATORY JOURNAL

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use

(2017) Jeffrey Hafkin et al.   EUROPEAN RESPIRATORY JOURNAL

Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?

(2017) Amber Kunkel et al.   LANCET INFECTIOUS DISEASES

Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management

(2016) Lorenzo Guglielmetti et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis

(2016) Lorenzo Guglielmetti et al.   EUROPEAN RESPIRATORY JOURNAL

Rapid emergence ofMycobacterium tuberculosisbedaquiline resistance: lessons to avoid repeating past errors

(2016) Nicolas Veziris et al.   EUROPEAN RESPIRATORY JOURNAL

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline

(2016) Marina Tadolini et al.   EUROPEAN RESPIRATORY JOURNAL

Bedaquiline plus delamanid for XDR tuberculosis

(2016) Marie Lachâtre et al.   LANCET INFECTIOUS DISEASES

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

(2015) Alexander S. Pym et al.   EUROPEAN RESPIRATORY JOURNAL

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

(2015) N. Ndjeka et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

(2015) Guido V. Bloemberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug

(2014) Sarah C. McLeay et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis

(2014) J. Peter Cegielski et al.   CLINICAL INFECTIOUS DISEASES

Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort

(2014) L. Guglielmetti et al.   CLINICAL INFECTIOUS DISEASES

Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

(2014) Andreas H. Diacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism

(2014) Anil Koul et al.   Nature Communications

First novel anti-tuberculosis drug in 40 years

(2013) Randy Osborne   NATURE BIOTECHNOLOGY

Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

(2012) A. H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

(2012) Vija Skripconoka et al.   EUROPEAN RESPIRATORY JOURNAL

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

(2012) Andreas H Diacon et al.   LANCET

Delamanid for Multidrug-Resistant Pulmonary Tuberculosis

(2012) Maria Tarcela Gler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

(2011) A. H. Diacon et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

(2009) Andreas H. Diacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transmission of MDR and XDR Tuberculosis in Shanghai, China

(2009) Ming Zhao et al.   PLoS One